Singapore - English - HSA (Health Sciences Authority)

vivo surgical private limited - general hospital - klaro™ in vivo surgical lighting is intended to provide direct localized “flood-lighting” from within the open surgical site.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - hepatitis a virus antigen, quantity: 160 elisa unit - injection, suspension - excipient ingredients: neomycin; formaldehyde; bovine serum albumin; polysorbate 80; aluminium hydroxide hydrate; phenoxyethanol; glucose monohydrate; ascorbic acid; sodium chloride; calcium chloride dihydrate; ferric nitrate nonahydrate; potassium chloride; magnesium sulfate heptahydrate; monobasic potassium phosphate; dibasic sodium phosphate; adenine sulfate dihydrate; adenosine triphosphate disodium; adenosine phosphate; cholesterol; deoxyribose; glutathione; guanine hydrochloride monohydrate; sodium hypoxanthine; ribose; sodium acetate; thymine; uracil; sodium xanthine; dl-alanine; arginine hydrochloride; dl-aspartic acid; cysteine hydrochloride; cystine dihydrochloride; dl-glutamic acid; glutamine; glycine; histidine hydrochloride; isoleucine; hydroxyproline; dl-leucine; lysine hydrochloride; dl-methionine; dl-phenylalanine; proline; dl-serine; dl-threonine; dl-tryptophan; tyrosine disodium; dl-valine; biotin; ergocalciferol; calcium pantothenate; choline chloride; folic acid; inositol; menadione; nicotinic acid; nicotinamide; aminobenzoic acid; pyridoxal hydrochloride; pyridoxine hydrochloride; riboflavine; thiamine hydrochloride; retinol acetate; dl-alpha-tocopheryl phosphate disodium - vivaxim is indicated for simultaneous active immunisation against typhoid fever and hepatitis a virus infections in subject's aged 16 and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

biocelect pty ltd - salmonella typhi, quantity: 2000 million organisms - capsule, enteric - excipient ingredients: sucrose; ascorbic acid; protein hydrolysate; ethylene glycol; lactose; hypromellose phthalate; erythrosine; iron oxide red; titanium dioxide; magnesium stearate; diethyl phthalate; gelatin; iron oxide yellow - vivotif oral is indicated for active immunisation against typhoid in adults and children above 6 years of age. effectiveness in children below 6 years of age is not known at present.

United States - English - NLM (National Library of Medicine)

idorsia pharmaceuticals ltd - daridorexant (unii: lmq24g57e9) (daridorexant - unii:lmq24g57e9) - quviviq is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [see clinical studies (14.1)] . quviviq is contraindicated: - in patients with narcolepsy. - in patients with a history of hypersensitivity to daridorexant or any components of quviviq. angioedema with pharyngeal involvement has been reported [see adverse reactions (6.2)] . pregnancy exposure registry there will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to quviviq during pregnancy. pregnant women exposed to quviviq and healthcare providers are encouraged to call idorsia pharmaceuticals ltd at 1-833-400-9611. risk summary there are no available data on quviviq use in pregnant women to evaluate for drug-associated risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. in animal reproduction studies, oral administration of daridorexant to pregnant rats and rabbits during the period of organogenesi

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - conjugated estrogens, quantity: 0.45 mg; bazedoxifene acetate, quantity: 22.56 mg (equivalent: bazedoxifene, qty 20 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; hypromellose; microcrystalline cellulose; hyprolose; macrogol 400; magnesium stearate; sucrose palmitate; ascorbic acid; powdered cellulose; calcium phosphate; sucrose; propylene glycol; purified water; isopropyl alcohol; iron oxide black; titanium dioxide; iron oxide red; polydextrose; povidone; hyetellose; maltitol solution; poloxamer - duavive is indicated for treatment of moderate to severe vasomotor symptoms associated with menopause in women with a uterus.,- duavive should be used for the shortest duration consistent with treatment goals and risks for the individual woman.,- experience in women older than 65 years is limited.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - salmonella typhi vi polysaccharide 25ug (salmonella typhi vi polysaccharide (ty2 strain)); hepatitis a virus formaldehyde inactivated, gbm strain 160 u - solution for injection - active: salmonella typhi vi polysaccharide 25ug (salmonella typhi vi polysaccharide (ty2 strain)) excipient: dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride water for injection active: hepatitis a virus formaldehyde inactivated, gbm strain 160 u excipient: aluminium hydroxide as aluminium formaldehyde medium 199 phenoxyethanol as 2-phenoxyethanol solution 2.5µl - vivaxim® is indicated for simultaneous active immunisation against typhoid fever and hepatitis a virus infections in subjects aged 16 and older.

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - oestrogens conjugated, bazedoxifene - postmenopause - conjugated estrogens and bazedoxifene - duavive is indicated for:treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate.the experience treating women older than 65 years is limited.

European Union - English - EMA (European Medicines Agency)

idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - sleep initiation and maintenance disorders - psycholeptics - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.

United States - English - NLM (National Library of Medicine)

jaymac pharmaceuticals llc - folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), ferrous fumarate (unii: r5l488ry0q) (iron - unii:e1uol152h7), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol acetate (unii: 9e8x80d2l0) (.alpha.-tocopherol - unii:h4n855pnz1), thiamine mononitrate (unii: 8k0i04919x) (thiamine - unii:x66nso3n35), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), pyridoxine hydrochlorid - folic acid 1 mg - viva® ct prenatal chewable is indicated for the distinct nutritional requirements of individuals in need of prenatal/postnatal dietary supplementation as determined by a licensed medical practitioner. this product can be used fordietary management prior to conception. viva® ct prenatal chewable should be administered under the supervision of a licensed medical practitioner. viva® ct prenatal chewable is contraindicated in individuals with a known hypersensitivity to any of the ingredients.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

viva life science sdn. bhd. - wheat sprout powder; tomato powder; strawberry powder; spinach powder; pineapple powder; parsley powder; papaya powder; orange powder; carrot extract; bean sprout powder; alfalfa powder; carrot powder; cabbage powder -